Company Filing History:
Years Active: 2000-2003
Title: The Innovative Contributions of Robin Dean
Introduction
Robin Dean is a notable inventor based in Mountain View, CA. He has made significant contributions to the field of biochemistry, particularly in the development of novel peptides that have potential therapeutic applications. With a total of 2 patents, Dean's work is paving the way for advancements in medical treatments.
Latest Patents
Dean's latest patents focus on voltage-gated calcium channel antagonists. These patents describe a novel class of peptides that selectively block class E voltage-gated calcium channels. The class is exemplified by HG peptides, such as HG-1, which are isolated from the venom-producing cells of the tarantula Hysterocrates gigas. The patents also disclose methods for producing these blocking peptides, which have utility in inhibiting oxytocin release and can be used as anticonvulsants.
Career Highlights
Robin Dean is currently associated with Elan Pharmaceuticals, Inc., where he continues to innovate and contribute to the field. His work has garnered attention for its potential impact on treating various medical conditions through the modulation of calcium channels.
Collaborations
Dean collaborates with esteemed colleagues, including Robert W. Newcomb and Andrew L. Palma. Their combined expertise enhances the research and development efforts at Elan Pharmaceuticals.
Conclusion
Robin Dean's innovative work in developing voltage-gated calcium channel antagonists showcases his commitment to advancing medical science. His contributions are expected to have a lasting impact on therapeutic strategies in the future.